A test tube labelled with the vaccine is seen in front of COVID-19 and stock graph logo in this illustration taken.
Illustration from ReutersNovavax Inc is doubling its COVID-19 vaccine manufacturing capacity to two billion doses under an agreement with Serum Institute of India, the US company said on Tuesday.In August, Novavax signed a deal with Serum Institute, the worlds largest producer of vaccines, to produce a minimum of one billion doses of its vaccine candidate for low-and middle-income countries and India.As part of the expanded agreement, Serum Institute will also manufacture the antigen component of the vaccine, which is dubbed NVXCoV2373.The US companys vaccine is in mid-stage trials after an early-stage trial showed it produced high levels of antibodies against the novel coronavirus.Other drugmakers such as Pfizer Inc and Moderna Inc have already begun large late-stage studies of their experimental vaccines.